The abstract is read at the publisher; the summary is JClub's.
Blood-based biomarker testing for Alzheimer disease is being used in US clinical practice, with this cohort study quantifying testing rates alongside patient, clinician, and care-event patterns.
- Why it matters: The field lacks clear, real-world estimates of how often blood-based biomarker tests are ordered and how testing aligns with patient profiles and subsequent diagnostic or treatment activity.
- What they did: In a US cohort study, investigators assessed rates of blood-based biomarker testing for Alzheimer disease and examined associations with patient characteristics, ordering clinician specialty, and diagnostic and treatment events.
- The result: The findings provide a descriptive picture of current clinical use in the US and identify which patient and clinician factors are linked to testing and related care steps.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.